Clinical development of a dendritic-cell vaccine therapy for acute myeloid leukaemia

Informazioni relative al progetto

AML-VACCiN

ID dell’accordo di sovvenzione: 667713

DOI 10.3030/667713

Progetto chiuso

Data della firma CE 9 Dicembre 2015

Data di avvio 1 Gennaio 2016

Data di completamento 30 Settembre 2020

Finanziato da

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Costo totale € 8 278 716,25

Contributo UE € 6 001 482,00

Coordinato da

STICHTING AMSTERDAM UMC
Netherlands

Risultati finali

Other (1)

Document providing the logo and templates for a uniform corporate look

Websites, patent fillings, videos etc. (2)

Press release on the outcome of the interim analysis on effect DCP-001 vaccination on MRD
Press release on the completion of the Phase IIb study

Documents, reports (2)

Cumulative Expenditure report

Cumulative expenditure report required upon activation of Article 205 GA due to the existence of a 24 month reporting period to be submitted by 30 September 2020

Communication and dissemination plan